Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey

R. Correa , N. Vidal , A. Quesada-García , R. Marcos , J. Muñoz del Toro , J. Muñoz-Rodríguez
{"title":"Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey","authors":"R. Correa ,&nbsp;N. Vidal ,&nbsp;A. Quesada-García ,&nbsp;R. Marcos ,&nbsp;J. Muñoz del Toro ,&nbsp;J. Muñoz-Rodríguez","doi":"10.1016/j.acuroe.2023.08.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.</p></div><div><h3>Objectives</h3><p>To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.</p></div><div><h3>Materials &amp; methods</h3><p>A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).</p></div><div><h3>Results</h3><p>The annual incidence of PCa was 24,057 in participating hospitals (<em>N</em> = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.</p></div><div><h3>Conclusion</h3><p>This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173578623001002/pdfft?md5=98e0c64d8ebb8a4637c34d8285caad92&pid=1-s2.0-S2173578623001002-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173578623001002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.

Objectives

To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.

Materials & methods

A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).

Results

The annual incidence of PCa was 24,057 in participating hospitals (N = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.

Conclusion

This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.

西班牙对局部前列腺癌和生化复发患者的管理:医疗调查。
前言:前列腺癌(PCa)患者的治疗方法是由临床实践指南确定的,这些指南是根据随机研究的证据水平制定的。在西班牙,临床实践中对这些指南的遵守程度尚不清楚:描述西班牙 PCa 患者在确诊时的情况,以及对局部 PCa 患者和 BCR 患者的管理:在专科医疗机构(85 名泌尿科医生 [UROs]、64 名放射肿瘤科医生 [ROs] 和 21 名肿瘤内科医生 [MOs])开展了一项医疗调查。本研究编制了三份调查问卷,其中包括 22 个问题(泌尿外科医生和放射肿瘤科医生)或 21 个问题(肿瘤内科医生):结果:参与研究的医院(N = 131)PCa 年发病率为 24 057 例。推断西班牙的年发病率为 40,531 例。估计西班牙 PCa 发病率为 221,689 例。值得注意的是,泌尿外科医生和放射科医生接诊的患者中,分别有 79% 和 80% 在确诊时患有局部 PCa。在三个专科中,活检是最常用的诊断方法,其次是腹盆腔计算机断层扫描。90%以上的 BCR 患者接受了标准检查。新一代成像检查和 PET 胆碱/PSMA 仍在使用中。目前,大多数局部 PCa 患者接受手术或放疗,而对于 BCR 患者,泌尿外科医师和放射科医师更倾向于放疗,放射科医师更倾向于单独或联合使用雄激素剥夺疗法:本研究描述了诊断时的患者概况,并概述了目前西班牙临床实践中对局部 PCa 和 BCR 的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信